Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a
Yüklə 4,39 Mb.
|
- Bu səhifədəki naviqasiya:
- Cancer de prostată în stadiu avansat;
- Profilaxia şi infecţiilor fungice invazive la pacienţii în procedura de transplant medular şi aflaţi sub terapie imunosupresoare cu doze mari, cu risc mare de a dezvolta infecţii fungice masive.
| Protocol: N030C
______________________________________________________________________________ | 423 |A04AA01| ONDANSETRONUM** | Protocol: A004C | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A04AA01 ONDANSETRONUM SOL. INJ. 2 mg/ml OSETRON 4 mg 2 mg/ml DR. REDDY'S LABORATORIES OSETRON 8 mg 2 mg/ml DR. REDDY'S LABORATORIES A04AA01 ONDANSETRONUM SOL. INJ./PERF. 2 mg/ml EMESET 4 mg/2 ml 2 mg/ml CIPLA (UK) LIMITED EMESET 8 mg/4 ml 2 mg/ml CIPLA (UK) LIMITED
OSETRON 4 mg 4 mg DR. REDDY'S LABORATORIES SETRONON 4 mg 4 mg PLIVA LJUBLJANA D.O.O. ZOFRAN 4 mg 4 mg GLAXO WELLCOME UK LTD. A04AA01 ONDANSETRONUM COMPR. ORODISPERSABILE 4 mg ONDARAN MD 4 mg 4 mg RANBAXY UK LTD. A04AA01 ONDANSETRONUM SOL. INJ. 4 mg/2 ml ZOFRAN 4 mg/2 ml 4 mg/2 ml GLAXO WELLCOME UK LIMITED A04AA01 ONDANSETRONUM SOL. INJ./PERF. 4 mg/2 ml SETRONON 4 mg/2 ml 4 mg/2 ml PLIVA LJUBLJANA D.O.O. A04AA01 ONDANSETRONUM COMPR. FILM. 8 mg OSETRON 8 mg 8 mg DR. REDDY'S LABORATORIES (UK) LTD SETRONON 8 mg 8 mg PLIVA LJUBLJANA D.O.O. A04AA01 ONDANSETRONUM COMPR. ORODISPERSABILE 8 mg ONDARAN MD 8 mg 8 mg RANBAXY UK LIMITED A04AA01 ONDANSETRONUM SOL. INJ. 8 mg/4 ml ZOFRAN 8 mg/4 ml 8 mg/4 ml GLAXO WELLCOME UK LIMITED A04AA01 ONDANSETRONUM COMPR. FILM. 4 mg OSETRON 4 mg 4 mg DR. REDDY'S LABORATORIES SETRONON 4 mg 4 mg PLIVA LJUBLJANA D.O.O. ZOFRAN 4 mg 4 mg GLAXO WELLCOME UK LTD. A04AA01 ONDANSETRONUM COMPR. ORODISPERSABILE 4 mg ONDARAN MD 4 mg 4 mg RANBAXY UK LTD. A04AA01 ONDANSETRONUM COMPR. FILM. 8 mg OSETRON 8 mg 8 mg DR. REDDY'S LABORATORIES (UK) LTD SETRONON 8 mg 8 mg PLIVA LJUBLJANA D.O.O. A04AA01 ONDANSETRONUM COMPR. ORODISPERSABILE 8 mg ONDARAN MD 8 mg 8 mg RANBAXY UK LIMITED A04AA01 ONDANSETRONUM SOL. INJ./PERF. 8 mg/4 ml SETRONON 8 mg/4 ml 8 mg/4 ml PLIVA LJUBLJANA D.O.O. _______________________________________________________________________________
| 424 |A04AA02| GRANISETRONUM** | Protocol: A004C | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A04AA02 GRANISETRONUM COMPR. FILM. 1 mg KYTRIL(R) 1 mg 1 mg ROCHE ROMANIA S.R.L.
KYTRIL 2 mg F. HOFFMANN LA ROCHE LTD. A04AA02 GRANISETRONUM SOL. INJ. 3 mg/3 ml KYTRIL 3 mg/3 ml ROCHE ROMANIA SRL A04AA02 GRANISETRONUM COMPR. FILM. 2 mg KYTRIL 2 mg F. HOFFMANN LA ROCHE LTD. ________________________________________________________________________________
| 425 |A04AA05| PALONOSETRONUM** | Protocol: A002C;| | | | | A004C | |_______|_______|____________________________________________|_________________| ________________________________________________________________________________ DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A04AA05 PALONOSETRONUM SOL. INJ. 250 µg/5 ml ALOXI 250 µg/5 ml HELSINN BIREX PHARMACEUTICALS LTD. ________________________________________________________________________________
| 426 |B03XA01| EPOETINUM ALFA*** | Protocol: L022B | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B03XA01 EPOETINUM ALFA SOL. INJ. 10000 ui/ml EPREX(R) 10000 UI 10000 ui/ml JOHNSON & JOHNSON D.O.O.
EPOKINE 1000 UI/0,5 ml 1000 UI/0.5 ml RENAMED FARMA S.R.L. EPREX(R) 1000 UI 1000 ui/0.5 ml JOHNSON & JOHNSON D.O.O.
EPOPHAR 2000 U.I. 2000 UI GULF PHARMACEUTICAL IND. S.R.L.
EPOKINE 2000 UI/0,5 ml 2000 UI/0.5 ml RENAMED FARMA S.R.L. EPREX(R) 2000 UI 2000 ui/0.5 ml JOHNSON & JOHNSON D.O.O.
EPOKINE 2000 UI/1 ml 2000 UI/1 ml RENAMED FARMA S.R.L. B03XA01 EPOETINUM ALFA SOL. INJ. 3000 ui/0.3 ml EPREX(R) 3000 UI 3000 ui/0.3 ml JOHNSON & JOHNSON D.O.O. B03XA01 EPOETINUM ALFA SOL. INJ. 40000 UI EPREX(R) 40000 UI 40000 UI JOHNSON & JOHNSON D.O.O. B03XA01 EPOETINUM ALFA SOL. INJ. 4000 UI EPOPHAR 4000 U.I. 4000 UI GULF PHARMACEUTICAL IND. S.R.L. B03XA01 EPOETINUM ALFA SOL. INJ. 4000 ui/0.4 ml EPOKINE 4000 UI/0,4 ml 4000 UI/0.4 ml RENAMED FARMA S.R.L. EPREX(R) 4000 UI 4000 ui/0.4 ml JOHNSON & JOHNSON D.O.O. B03XA01 EPOETINUM ALFA SOL. INJ. 4000 UI/1 ml EPOKINE 4000 UI/1 ml 4000 UI/1 ml RENAMED FARMA S.R.L. ________________________________________________________________________________
| 427 |B03XA01| EPOETINUM BETA*** | Protocol: L022B | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B03XA01 EPOETINUM BETA SOL. INJ. ÎN SERINGĂ PREUMPLUTĂ NEORECORMON 10000 UI 10000 UI/0,6 ml ROCHE REGISTRATION L B03XA01 EPOETINUM BETA SOL. INJ. ÎN SERINGĂ PREUMPLUTĂ NEORECORMON 1000 UI 1000 UI/0,3 ml ROCHE REGISTRATION L
PREUMPLUTĂ NEORECORMON 2000 UI 2000 UI/0,3 ml ROCHE REGISTRATION L
PREUMPLUTĂ NEORECORMON 30000 UI/0,6 ml 30000 UI/0,6 ml ROCHE REGISTRATION LTD.
PREUMPLUTĂ NEORECORMON 4000 UI 4000 UI/0,3 ml ROCHE REGISTRATION L
PREUMPLUTĂ NEORECORMON 5000 UI 5000 UI/0,3 ml ROCHE REGISTRATION L
PREUMPLUTĂ NEORECORMON 500 UI 500 UI/0,3 ml ROCHE REGISTRATION L ________________________________________________________________________________ ______________________________________________________________________________ | 428 |B03XA02| DARBEPOETINUM ALFA*** | Protocol: L022B | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B03XA02 DARBEPOETINUM ALFA SOL. INJ. ÎN SERINGĂ 10 µg/0.4 ml PREUMPLUTĂ ARANESP 10 µg/0.4 ml 10 µg/0.4 ml AMGEN EUROPE BV B03XA02 DARBEPOETINUM ALFA SOL. INJ. ÎN SERINGĂ 100 µg/0.5 ml PREUMPLUTĂ ARANESP 100 µg/0.5 ml 100 µg/0.5 ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 15 µg/0.375 ml AMGEN EUROPE BV 15 µg/0.375 ml B03XA02 DARBEPOETINUM ALFA SOL. INJ. ÎN SERINGĂ 150 µg/0.3 ml PREUMPLUTĂ ARANESP 150 µg/0.3 ml 150 µg/0.3 ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 20 µg/0.5 ml 20 µg/0.5 ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 30 µg/0.3 ml 30 µg/0.3 ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 300 µg/0.6 ml 300 µg/0.6 ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 40 µg/0.4 ml 40 µg/0.4 ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 50 µg/0.5 ml 50 µg/0.5 ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 500 µg/ml 500 µg/ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 60 µg/0.3 ml 60 µg/0.3 ml AMGEN EUROPE BV
PREUMPLUTĂ ARANESP 80 µg/0.4 ml 80 µg/0.4 ml AMGEN EUROPE BV ________________________________________________________________________________ ______________________________________________________________________________ | 429 |G03HA01| CYPROTERONUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ G03HA01 CYPROTERONUM COMPR. 50 mg ANDROCUR 50 mg SCHERING AG
ANDROCUR 50 mg SCHERING AG ________________________________________________________________________________
| 430 |H02AB02| DEXAMETHASONUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H02AB02 DEXAMETHASONUM SOL. INJ. 8 mg DEXAMETHASONE SODIUM 8 mg E.I.P.I.CO. MED S.R.L. PHOSPHATE H02AB02 DEXAMETHASONUM SOL. INJ. 8 mg/2 ml DEXAMED 8 mg/2 ml MEDOCHEMIE LTD. ________________________________________________________________________________
| 431 |J02AC02| ITRACONAZOLUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ J02AC02 ITRACONAZOLUM CAPS. 100 mg ITRACONAZOL 100 mg 100 mg TERAPIA S.A. OMICRAL 100 mg 100 mg MEDICO UNO PHARMACEUTICAL S.R.L. ORUNGAL 100 mg JANSSEN PHARMACEUTICA NV ________________________________________________________________________________ ______________________________________________________________________________ | 432 |J02AC03| VORICONAZOLUM** | Protocol: J012B | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ J02AC03 VORICONAZOLUM COMPR. FILM. 200 mg VFEND 200 mg 200 mg PFIZER LTD.
VFEND 200 mg 200 mg PFIZER LTD. J02AC03 VORICONAZOLUM PULB. PT. SUSP. ORALĂ 40 mg/ml VFEND 40 mg/ml 40 mg/ml PFIZER LTD. J02AC03 VORICONAZOLUM COMPR. FILM. 50 mg VFEND 50 mg 50 mg PFIZER LTD. ________________________________________________________________________________
| 433 |J02AC04| POSACONAZOLUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ J02AC04 POSACONAZOLUM SUSP. ORALĂ 40 mg/ml NOXAFIL SP 40 mg/ml 40 mg/ml SP EUROPE
Prescriere limitată: Profilaxia şi infecţiilor fungice invazive la pacienţii în procedura de transplant medular şi aflaţi sub terapie imunosupresoare cu doze mari, cu risc mare de a dezvolta infecţii fungice masive. ________________________________________________________________________________ ______________________________________________________________________________ | 434 |J02AX04| CASPOFUNGINUM** | Protocol: J010D | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ J02AX04 CASPOFUNGINUM PULB. PT. CONC. PT. 50 mg SOL. PERF. CANCIDAS 50 mg 50 mg MERCK SHARP & DOHME LTD J02AX04 CASPOFUNGINUM PULB. PT. CONC. PT. 70 mg SOL. PERF. CANCIDAS 70 mg 70 mg MERCK SHARP & DOHME LTD ________________________________________________________________________________ ______________________________________________________________________________ | 435 |L01XX35| ANAGRELIDUM*** | Protocol: L015D | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L01XX35 ANAGRELIDUM CAPS. 0.5 mg THROMBOREDUCTIN 0.5 mg ORPHA-DEVEL HANDELS UND VERTRIEBS GMBH ________________________________________________________________________________
| 436 |L04AA01| CICLOSPORINUM* | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L04AA01 CICLOSPORINUM CAPS. MOI 100 mg EQUORAL(R) 100 mg 100 mg IVAX-PHARMACEUTICALS S.R.O.
EQUORAL(R) 100 mg/ml IVAX-PHARMACEUTICALS S.R.O.
SANDIMMUN NEORAL(R) 100 mg/ml NOVARTIS PHARMA GMBH L04AA01 CICLOSPORINUM CAPS. MOI 25 mg CICLORAL(R) HEXAL(R) 25 mg 25 mg HEXAL AG EQUORAL(R) 25 mg 25 mg IVAX-PHARMACEUTICALS S.R.O.
SANDIMMUN NEORAL(R) 25 mg NOVARTIS PHARMA GMBH L04AA01 CICLOSPORINUM CAPS. MOI 50 mg CICLORAL(R) HEXAL 50 mg 50 mg HEXAL AG EQUORAL(R) 50 mg 50 mg IVAX-PHARMACEUTICALS S.R.O.
SANDIMMUN NEORAL(R) 50 mg NOVARTIS PHARMA GMBH ________________________________________________________________________________ ______________________________________________________________________________ | 437 |N02AA01| MORPHYNUM | | |_______|_______|____________________________________________|_________________|
Yüklə 4,39 Mb. Dostları ilə paylaş:
|